Dupilumab is a medicine used to treat a skin condition called prurigo nodularis (PN), which causes itchy bumps. This study will observe adults with PN who are treated with dupilumab to understand how well it works in real life and how it is used. The study will last up to 36 months, or until a patient decides to stop, is lost to follow-up, or passes away.

Key Points:

• Study Duration: Up to 3 years of follow-up.
• Participation Requirements: Must be 18 or older, able to complete questionnaires, and willing to consent.
• Exclusions: If you have used dupilumab recently or have conditions that make study participation difficult, you may not be eligible.

If you're interested, speak with your doctor to see if this study is a good fit for you. Remember, participating in studies helps scientists understand treatments better, but it's important to consider if it suits your situation.